Generational gains in cognitive capacity and dementia incidence rates in Western countries
Abstract Dementia incidence has been declining in Western societies for decades, but whether this reflects higher cognitive capacity entering old age, slower cognitive decline, or both remains unresolved. Analysing ~783,000 episodic memory assessments from ~219,000 individuals across five longitudinal cohorts, we find that later-born cohorts benefit from a double dividend: higher memory levels entering old age and slower rates of decline. The projected 20-year cohort advantage at age 80 is of sufficient magnitude to plausibly account for the observed 13% per-decade decline in dementia incidence reported in meta-analyses. Generational gains are disproportionately concentrated among the fastest-declining individuals, and are reflected in lower hippocampal atrophy rates in an independent sample. A formal bounding analysis shows that the double dividend is robust across a range of plausible period assumptions, consistent with environmental conditions operating across the lifespan having reshaped the architecture of human cognitive aging.
Authors
- Dídac Vidal-piñeiro A (ORCID: https://orcid.org/0000-0001-9997-9156)
- Ole Jørgen Røgeberg (ORCID: https://orcid.org/0000-0003-3129-6687)
- Anders M. Fjell (ORCID: https://orcid.org/0000-0003-2502-8774)
- Gabriela Lunansky (ORCID: https://orcid.org/0000-0001-6226-2258)
- Kristine Beate Walhovd (ORCID: https://orcid.org/0000-0003-1918-1123)
- Edvard Grødem (ORCID: https://orcid.org/0000-0003-1915-1872)
Institutions
- Oslo University Hospital (NO)
- University of Oslo (NO)
- Amsterdam University Medical Centers (NL)
- Ragnar Frisch Centre for Economic Research (NO)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Nature Medicine
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1038/s41591-026-04759-y
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Foundation for the National Institutes of Health
- Mayo Clinic
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Roche
- Atlantic Philanthropies
- U.S. Social Security Administration
- Biogen
- University of Southern California
- Mayo Foundation for Medical Education and Research
- Meso Scale Diagnostics
- University of Michigan
- BioClinica
- Novartis Pharmaceuticals Corporation
- McGill University
- Fondation Brain Canada
- Northern California Institute for Research and Education
- Health Research Board
- Government of the United Kingdom
- GHR Foundation
- Elsie and Marvin Dekelboum Family Foundation
- An Roinn Sláinte
- Government of Canada
- National Institute for Health and Care Research
- Department of Health and Social Care
- European Commission
- Commonwealth Scientific and Industrial Research Organisation
- Trinity College Dublin
- Eisai
- Max-Planck-Gesellschaft
- Universitetet i Oslo
- Norges Forskningsråd
- Schuler-Stiftung
- Servier
- Nasjonalforeningen for Folkehelsen
- H. Lundbeck A/S
- IXICO
- National Institutes of Health
- Genentech
- Johnson and Johnson
- Pfizer Canada
- Avid Radiopharmaceuticals
- Canadian Institutes of Health Research
- Fonds de Recherche du Québec - Santé
- Directorate-General for Employment, Social Affairs and Inclusion
- Livsvitenskap, Universitetet i Oslo
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- H2020 European Research Council
- FP7 Ideas: European Research Council